Claritin Rebate Settlement Leaves Door Open For Boston Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering-Plough's July 30 settlement with the Philadelphia U.S. Attorney does not preclude additional criminal prosecution of the company over its Medicaid "best price" reporting for Claritin
You may also be interested in...
Schering Doubles Legal Reserves To $500 Mil. For Boston Investigation
Company adds $250 mil. in litigation reserves primarily relating to the Boston U.S. Attorney’s investigation into Schering’s marketing practices. Schering also took a $9 mil. charge for facility consolidation during the second quarter.
Schering Doubles Legal Reserves To $500 Mil. For Boston Investigation
Company adds $250 mil. in litigation reserves primarily relating to the Boston U.S. Attorney’s investigation into Schering’s marketing practices. Schering also took a $9 mil. charge for facility consolidation during the second quarter.
Schering-Plough Physician Payments May Be Next Target Of Federal Prosecutors
Increasing media coverage, including a CNN interview with the Boston U.S. Attorney and the Neurontin “whistleblower,” has raised the profile of allegations that Schering offered inappropriate payments to physicians to prescribe Intron-A.